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Background. Reports on the general population indicated
that decreased endothelial-mediated vasodilation has a prog-
nostic impact on cardiovascular (CV) morbidity and mortality.
Flow-dependent vasodilation of conduit arteries and ischemia-
induced forearm reactive hyperemia are impaired in end-stage
renal disease (ESRD). Whether deterioration of vasodilator
function in ESRD patients has a prognostic impact has not been
documented. The aim of this study was to determine whether
the impaired forearm postischemic vasodilation is an indepen-
dent predictor of mortality in ESRD patients, independently
from CV end-organ damages, which are usually associated with
decreased vasodilatory response.
Methods. Common carotid artery intima-media thickness
(CCA-IMT), aortic stiffness (pulse wave velocity - PWV), and
LV mass (LVM) were determined for 78 stable ESRD patients
on hemodialysis. Forearm postischemic vasodilation [flow debt
repayment (FDR)] was measured by venous plethysmography.
All-cause mortality served as the outcome variable over a me-
dian follow-up of 60 ± 27 months.
Results. Twenty-four deaths occured (16 of CV origin). Ac-
cording to Cox regression adjusted for age, CCA-IMT, LVM,
and PWV, all-cause mortality was independently associated
with decreased FDR (RR 0.69 for every 10% increase; 95%
CI 0.56–0.85; P = 0.0006) and increased aortic PWV (RR 1.16
for 1 m/s increase; 95% CI 1.04–1.29; P = 0.0091).
Conclusion. Our data indicate that lower postischemic fore-
arm reactive hyperemia is associated with all-cause mortality
of ESRD patients, independently of the presence of end-organ
damage such as LVH or arteriosclerosis.
Several reports on the general population have indi-
cated that decreased endothelial-mediated vasodilation
of conduit arteries has a prognostic impact on cardiovas-
cular (CV) morbidity and mortality [1–5], and is associ-
ated with CV end-organ damage such as left ventricular
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hypertrophy (LVH) and carotid artery wall thickening
[6–8]. Flow-dependent vasodilation of peripheral conduit
arteries and ischemia-induced forearm reactive hyper-
emia are impaired in ESRD patients, and are also as-
sociated with CV end-organ damage such as LVH, highly
calcified atherosclerosis, arterial stiffening, and increased
carotid artery intima-media thickness (IMT) [9, 10]. All
of the above-mentioned end-organ damages are associ-
ated with mortality in these patients [11–14]. The present
study was designed to determine whether the alterations
in ischemia-induced hyperemic response evaluated non-
invasively by forearm postichemic vasodilation has an




Patients followed in a single unit were included in
the study between the September 1, 1994 and May
31, 1996, and were followed-up until September 30,
2002, the reference date for analysis of survival time.
Patients were eligible for inclusion when: (1) they had
been on hemodialysis (HD) at least for 3 months (58 ±
21 months; mean ± SD; range 10–84); (2) they had
no clinically evident cardiovascular disease (CVD);
and (3) they agreed to participate in the study which
was approved by our Institutional Review Board. In
all, 78 (54 males and 24 females) patients fulfilled the
entry criteria. Patients who underwent renal trans-
plantation (N = 5) and patients who moved away
(N = 1) were censored on the day of transplantation
or departure. All but 6 patients were Caucasian, and 7
patients had diabetes mellitus. The follow-up was 60 ±
27 months (range 10–96 months). Data on mortality were
obtained for the entire cohort. The age off the cohort at
inclusion was 54 ± 15 years (range 23–81 years). During
follow-up, all patients were dialyzed using the same
techniques, as previously reported in detail [15]. Patients
received epoietin when necessary to maintain predialysis
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Fig. 1. Schematic representation of a reactive hyperemic response in
the human forearm blood flow after 5 minutes of ischemia. See Methods
for definitions.
hemoglobin level between 10–12 g/dL, and 60 patients
received antihypertensive therapy [angiotensin-
converting enzyme (ACE) inhibitor, calcium channel
blocker, or b-blocker alone or in combination].
Data collection and hemodynamic measurements
Brachial blood pressure (BP) was measured with a
mercury sphygmomanometer after 15 minutes of recum-
bency. Phases I and V of the Korotkoff sounds were taken
as the systolic (SBP) and diastolic BP (DBP), respectively.
Five measurements taken at 2-minute intervals were av-
eraged. Common carotid artery intima-media thickness
(CCA-IMT) was measured on the far wall with a high-
resolution B-mode 7.5-MHz transducer (Wall-Track Sys-
tem; Pie Medical, Maastricht, The Netherlands) with
computer-assisted acquisition, storage, and processing
with specific software (Eurequa; TSA, Meudon, France)
[16]. Aortic pulse wave velocity (PWV) was determined
using transcutaneous Doppler flow recordings with a
nondirectional Doppler unit (10 MHz; SEGA M842,
Paris, France) and the foot-to-foot method from the CCA
and the femoral artery in the groin [15]. Echocardio-
graphic determination of LV mass according to the Penn
convention [17] was performed using a Hewlett-Packard
(Palo Alto, CA, USA) Sonos 100 device equipped with a
2.25-MHz probe.
Forearm blood flow (FBF in mL/100 mL/min) was mea-
sured by venous occlusion plethysmography (Perivein;
Janssens, Belgium), as previously described [10](Fig. 1).
A mercury strain gauge was placed on the largest part
of the arm distal to the humeral epicondyle. A venous
occlusion cuff was placed around the upper arm and con-
nected to an automatic inflator. An arterial occlusion cuff
was placed proximal to the venous cuff and the gauge.
After control flow measurements, the arterial cuff was
inflated to 300 mm Hg for 5 minutes. Ten seconds before
deflating the arterial cuff, the venous cuff was inflated
to 50 mm Hg. At time “zero,” the arterial cuff was de-
flated and the FBF was immediately measured, with rep-
etition of measurements every 15 seconds until resting
flow levels were reached, then every minute until 5 min-
utes. The following parameters were determined (Fig. 1):
the flow debt (A, area under the curve between the start
and end of ischemia period), the postischemic peak flow,
the duration of the hyperemia, the excess hyperemic flow
(B, area under the curve between the release of ischemia
and duration of hyperemia), and the flow-debt repayment
(FDR = B/A). All measurements were made with a wrist
cuff inflated at 20 mm Hg above the SBP. Forearm hemo-
dynamic parameters and response to reactive hyperemia
in age and blood pressure matched nonuremic subjects
were previously published [10].
Laboratory methods
Blood was obtained before hemodynamic investiga-
tions after an overnight fast. The plasma was sepa-
rated without delay at 4◦C in a refrigerated centrifuge
and stored at −20◦C until determinations were per-
formed. Routine biochemical parameters were deter-
mined using standard methods, and serum albumin,
plasma fibrinogen, and C-reactive protein (CRP) were
measured nephelometrically. Total plasma homocysteine
was assessed with fluorometric high-performance liquid
chromatography.
Statistical analysis
Data are expressed as mean ± SD. Information com-
piled from the questionnaire filled out at entry into the
study included personal and family histories. Causes of
death (WHO International Classification of Disease, 9th
edition) were obtained from death certificates, hospital
records forms, and autopsy data reviewed by the authors.
During the follow-up period, we recorded 24 deaths, in-
cluding 16 fatal CV events.
Univariate and multivariate correlations studies were
done using least-squares method. The outcome event
studied was all-cause mortality. The primary analyses
concerned the survival curves and Cox proportional haz-
ards model. Survival was estimated by the Kaplan-Meier
product-limit method and compared by the Mantel (log-
rank) test. Factors prognostic of survival were identified
with the use of the univariable Cox proportional haz-
ards regression model. The assumption of proportional
hazards over the time and assumption of linearity was
verified before the analyses and was met by all covari-
ates. Due to high colinearity between several variables,
data reduction procedure was used to determine the fi-
nal Cox model. The number of variables in the model was
reduced using automatic forward stepwise selection algo-
rithm. The variable with the strongest association with the
outcome was entered first, followed by the next strongest,
until all variables that are related to the outcome (P <
0.05) are entered into the model. Any variable that has
been entered but is no longer significant after other
variables have been added to the model is sequentially
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Table 1. Clinical and hemodynamic characteristics of ESRD patients
Variable ESRD
Body mass index kg/m2 24 ± 4
Systolic blood pressure mm Hg 148 ± 28
Diastolic blood pressure mm Hg 82 ± 14
Left ventricular mass index g/m2 181 ± 42
Carotid intima-media thickness lm 800 ± 98
Aortic pulse wave velocity m/s 11.2 ± 3.2
Baseline forearm blood flow mL/100 mL/m 4 ± 1.3a
Peak forearm blood flow mL/100 mL/m 28 ± 10a
Flow debt repayment % 87 ± 32a
Duration of hyperemia seconds 103 ± 40a
Tobacco pack/year 12 ± 18
Hemoglobin g/L 108 ± 21
Total cholesterol mmol/L 5.2 ± 1.2
Triglycerides mmol/L 2 ± 1
Serum albumin g/L 40 ± 2.2
Serum CRP mg/L 11.2 ± 12
Homocysteine lmol/L 36.7 ± 14.5
FBF is forearm blood flow. Duration of hyperemia 127 ± 36 (seconds). Baseline
FBF 3.5 ± 1.3 (mL/100 mL/m); peak FBF 29.2 ± 9.1 (mL/100 mL/m); Flow debt
repayment 116 ± 31(%).
aNormal values for age- and blood pressure-matched nonuremic subjects [10].
deleted. The following variables were tested (with dura-
tion of HD at inclusion as a time entry variable): aortic
PWV, FDR, CRP, CCA-IMT, age, and LV mass index.
Variables were considered to be significant for P < 0.05
in the final multivariable model.
All tests were performed using NCSS 2001 and SAS
software (J. Hintz, Kaysville, Utah, USA).
RESULTS
The clinical and hemodynamic characteristics are
shown in Table 1. Many of the studied parameters were
correlated among themselves (Table 2).
Outcome and prognostic impact of FDR
During follow-up, 24 deaths occurred (16 of CV origin).
RR and 95% CI for different variables with univariable
Cox regression and after adjustment for confounding
variables are shown in Table 3. After the adjustment aor-
tic PWV and FDR emerged as being the only two vari-
ables independently associated with all-cause mortality.
Figure 2 shows the probability of all-cause survival ac-
cording to median value of FDR.
DISCUSSION
The salient result of this study is the demonstration
that ESRD patients have significantly impaired vascu-
lar adaptation to ischemic stimuli and that lower postis-
chemic forearm vasodilation is an independent predictor
of all-cause mortality. The two independent prognostic
factors for mortality are impairments of large artery func-
tion, characterized by increased aortic stiffness, and im-
pairment of the microcirculation characterized by lower
FDR. This association existed after adjustment for CV
end-organ damage, including LVH and CCA-IMT.
In many studies analyzing the association between dif-
ferent vasodilatory responses and outcomes, the Cox
proportional analyses were adjusted to conventional risk
factors, such as age, sex, BP, blood lipids, diabetes, smok-
ing, or the extent of vessel disease [1–5]. Nevertheless,
in patients with hypertension and CVD, arterial dysfunc-
tion (including reactive vasodilation) is also associated
with markers of end-organ damage such as CCA-IMT,
LVH, and extent of intramural plaque [6–8]. Because all
of these end-organ damages were considered to be risk
factors independently associated with the prognosis, the
exact relevance and independence of arterial vasodila-
tory responses still needs to be confirmed. This remark
is especially relevant for ESRD patients, in whom it has
been shown that (according to the variables introduced
into the Cox models) the LVH, the CCA-IMT, aortic ar-
teriosclerosis, or low-grade systemic inflammation were
independent predictors of mortality [11–14]. As shown
herein, all of these parameters were also associated with
lower FDR (Table 2), and the proportional hazards model
had to be adjusted not only to conventional risk factors
but also to the extent of end-organ damage. Our data
show that the relevance of impaired postischemic hyper-
emia as a prognostic factor was significant after the adjust-
ment for end-organ damage such as LVH or CCA-IMT.
Several studies on general populations have shown
that the decrease of coronary or forearm endothelium-
mediated vasodilation is associated with the occurrence
of CV events in follow-up studies. Using coronary an-
giography and determination of endothelium dependent
flow reserve, Al Suwaidi et al [1] showed higher inci-
dence of CV events in patients with severe endothelial
dysfunction, assessed as microcirculatory response to
acetylcholine. Similar results were obtained by studying
coronary vasomotor response [2]. Additional informa-
tion was provided by Halcox et al [5], who showed that
epicardial and microvascular coronary endothelial dys-
function independently predict acute CV events in pa-
tients with and without coronary artery disease (CAD).
The prognostic value of endothelial dysfunction was also
demonstrated using less invasive methods, such as fore-
arm endothelial dysfunction evaluated by strain-gauge
plethysmography and intra-arterial infusions of acetyl-
choline in patients with stable CAD or uncomplicated
hypertension [3, 4].
While the response of large conduit arteries to ischemia
is mediated by endothelium-mediated increase in arte-
rial diameter and/or flow velocity, whether decreased
postischemic hyperemia observed in the present study
reflects endothelial dysfunction in ESRD patients is less
clear. Myogenic, neural, and accumulation of vasodilator
substances, such as adenosine, prostaglandins, and/or is-
chemic metabolites, play critical roles in the reactive hy-
peremic response due to transient interruption of the
blood supply. The adjustment of the microcirculation to
ischemia is also mediated by recruitment of microvessels.
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Table 2. Correlation matrix report: FDR as a dependent variable
Age SBP Aix PWV SAlb CCAIMT LV mass CRP FDR
Age years 1.000
SBP mm Hg 0.116 1.000
Aix % 0.376b 0.439c 1.000
PWV m/s 0.605c 0.411c 0.458c 1.000
Salb g/L −0.476c −0.199 −0.379b −0.423c 1.000
CCAIMT lm 0.587c 0.401c 0.412c 0.620c −0.346b 1.000
LVM g/m2 0.178 0.379c 0.262a 0.347b −0.120 0.565c 1.000
CRP mg/L 0.543c 0.193 0.315a 0.557c −0.639c 0.527c 0.228a 1.000
FDR % −0.489c −0.300b −0.492c −0.544c 0.511c −0.561c −0.262a −0.517c 1.000
Abbreviations are: SBP, systolic BP; Aix, augmentation index; PWV, pulse wave velocity; Salb, serum albumin; CCAIMT, common carotid artery intima-media




Table 3. Cox regression for all-cause mortality in ESRD patients
UNIVARIABLE
Wald
Variable RR and 95% CI P value Z-value
Age years 1.05 (1.02–1.09) 0.0025 3.020
Gender 0-M, 1-F 0.64 (0.24–1.75) 0.389 −0.980
Diabetes 0-no, 1-yes 2.23 (0.65–7.60) 0.203 0.712
Body mass index kg/m2 1.04 (0.93–1.16) 0.477 1.274
Duration HD months 1.0 (0.99–1.02) 0.919 1.056
Systolic BP (mmHg) 1.02 (1.0–1.03) 0.0321 2.128
Diastolic BP (mmHg) 0.97 (0.93–1.01) 0.081 −1.749
LV mass index (g/m2) 1.02 (1.01–1.03) 0.0212 2.390
Carotid IMT lm 1.02 (1.01–1.04) 0.0006 3.524
Aortic PWV m/s 1.29 (1.17–1.42) 0.00001 4.979
Flow debt repayment (10%) 0.59 (0.48–0.73) 0.00001 −4.786
Smoking pack/years 1.03 (1.01–1.05) 0.0004 3.519
Hemoglobin g/L 0.96 (0.87–1.05) 0.363 −0.938
Total cholesterol mmol/L 1.10 (0.75–1.62) 0.751 0.495
HDL-C mmol/L 3.13 (0.90–10.9) 0.0728 1.798
LDL-C mmol/L 1.01 (0.57–1.63) 0.959 0.052
Triglycerides mmol/L 1.18 (0.82–1.69) 0.368 0.903
Serum albumin g/L 0.79 (0.67–0.92) 0.0023 −3.055
Serum CRP mg/L 2.53 (1.60–4.00) 0.0001 3.963
Homocystein lmol/L 1.00 (0.96–1.03) 0.509 −0.851
MULTIVARIABLE
Flow debt repayment (10%) 0.69 (0.56–0.85) 0.0006 −3.417
Aortic PWV m/s 1.16 (1.04–1.29) 0.0091 2.608
Abbreviations are: HD, hemodialysis; BP, blood pressure; LV, left ventricu-
lar; IMT, intima-media thickness; PWV, pulse wave velocity; HDL, high-density
lipoproteins; LDL, low-density lipoproteins; CRP, C-reactive protein.
Structural changes in the microvasculature, including re-
duced capillary density, were described in ESRD patients
[18], and alterations of FDR could be due to altered
vasodilation, less microvascular density, and/or abnor-
mal vessel recruitment. However, several arguments go
against the latter. The principal one is that the baseline
and peak FBF are similar in controls and ESRD patients
[10], and the principal impairment observed is a shorter
duration of hyperemia [10]. The peak reactive hyperemic
response of FBF is not affected by L-NMMA, suggesting
that nitric oxide (NO) plays minimal role in vasodilation
at peak flow [19, 20]. On the contrary, the duration of the
hyperemic response is reduced with L-NMMA, indicat-
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Fig. 2. Probability of all-cause survival between patients with flow debt
repayment (FDR)> or< median value.
taining vasodilation after peak vasodilation [19, 21, 22].
The normal peak flow and rapid exhaustion of the hyper-
emic response observed in ESRD patients is more in line
with possible alterations of NO-associated production or
release [23–25].
The association of all-cause mortality with aortic PWV
in ESRD patients reflects the advanced progression of
athero-arteriosclerosis of large capacitive vessels [12, 26].
Vascular dysfunction was shown to be associated with
low-grade systemic inflammation and associated with in-
creased serum CRP and decreased serum albumin [27].
In ESRD patients, these latter two parameters are as-
sociated with end-organ damage, like FDR, CCA-IMT,
the presence of atheromatous plaques, and poor prog-
nosis [28–30]. In nonadjusted Cox proportional hazards
models the lower serum albumin and higher CRP were
significantly associated with increased hazard ratio for all-
cause mortality, but also with abnormal forearm vasodila-
tion and aortic PWV. However, upon introduction of the
latter, this association was no longer retained after the ad-
justment for aortic PWV and FDR. The present study has
several limitations. The principal limitation is the small
sample size and the possibility that this population is not
representative of larger HD patient populations. Indeed,
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the mean age of the included patients was lower than
that of those now being treated in HD units; the frequen-
cies of comorbidities, including CVD, are lower, and that
of diabetes lower than in North America and northern
Europe. The cumulative all-cause mortality during the
5-year follow-up was 29.5%, and the studied population
is at lower risk than usual HD patients populations. The
limited sample size could have an impact on the model-
ing using Cox regression, and the lack of relationship of
any of the other variables could be related to the sam-
ple size. Finally, another limitation could be the relation-
ship between reactive forearm hyperemia and vasomotor
alterations of coronary and systemic arteries. In a pre-
vious study a close relation of vasodilatory function in
the human coronary and forearm circulations has been
demonstrated, and the latter can be a useful surrogate in
assessing the systemic endothelial function [31].
CONCLUSION
The results of this study demonstrated that forearm
reactive hyperemia was impaired in ESRD patients
due to the shorter duration of the hyperemic response.
This altered hyperemic response was a strong and in-
dependent predictor of all-cause mortality, in associa-
tion with arteriosclerosis of large capacitive arteries and
increased aortic PWV. The exact mechanisms responsi-
ble for decreased reactive hyperemia, such as possibility
of endothelial dysfunction, rarefaction of microcircula-
tion, and decreased recruitment of vessels should be
determined.
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